Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04537013 · ClinicalTrials.gov registry record · NA
Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee
A NA study, sponsored by Geistlich Pharma.
- Terminated
- Registry status
- NA
- Development phase
- 82
- Enrollment target
NCT04537013 is a NA study that was terminated before completion, run by Geistlich Pharma. The registered enrollment target is 82 participants.
The verdict
NCT04537013, a NA study, was terminated before completion, sponsored by Geistlich Pharma.
- TERMINATED
- Registry status
- NA
- Development phase
- 82 participants
- Enrollment target
Study Summary
Multi-center, prospective, concurrently controlled, non-randomized, double-blind (patient and assessor). Treatment of large chondral lesions in the knee with microfracture plus the Chondro-Gide® ACC is non-inferior to treatment of small chondral lesions treated with microfracture alone.
Interventions
- PROCEDURE Microfracture
- DEVICE Microfracture plus placement of Chondro-Gide® ACC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2020-08-26 |
| Est. Completion | 2025-09-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04537013
The ClinicalTrials.gov registry entry for NCT04537013 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geistlich Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Microfracture is the first listed.
NCT04537013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04537013 about?
NCT04537013 is a clinical study titled "Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee". Multi-center, prospective, concurrently controlled, non-randomized, double-blind (patient and assessor). Treatment of large chondral lesions in the knee with microfracture plus the Chondro-Gide® ACC is non-inferior to treatment of small chondral lesions treated with microfracture alone.
What is the current status of trial NCT04537013?
This trial is currently terminated. It is a NA study. The enrollment target is 82 participants. The study started on 2020-08-26. Estimated completion is 2025-09-29.
What interventions are being tested in trial NCT04537013?
The interventions under investigation include: Microfracture (PROCEDURE), Microfracture plus placement of Chondro-Gide® ACC (DEVICE).
Who is sponsoring clinical trial NCT04537013?
This trial is sponsored by Geistlich Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.